- Home
- VNO vs CORT Comparison
VNO vs CORT Comparison
Compare VNO & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VNO | CORT |
|---|---|---|
| Founded | 1946 | 1998 |
| Country | United States | United States |
| Employees | 3145 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 3.7B |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | VNO | CORT |
|---|---|---|
| Price | $30.41 | $57.85 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 5 |
| Target Price | $33.00 | ★ $96.50 |
| AVG Volume (30 Days) | ★ 1.7M | 1.1M |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.52% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $761,407,000.00 |
| Revenue This Year | N/A | $26.08 |
| Revenue Next Year | $5.42 | $26.98 |
| P/E Ratio | $7.08 | ★ N/A |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $24.57 | $28.66 |
| 52 Week High | $43.37 | $91.00 |
Technical Indicators
Market Signals| Indicator | VNO | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 52.57 | 71.78 |
| Support Level | $28.48 | $32.95 |
| Resistance Level | $30.42 | $90.00 |
| Average True Range (ATR) | 0.94 | 2.51 |
| MACD | -0.11 | 0.40 |
| Stochastic Oscillator | 40.71 | 92.42 |
Price Performance
Historical ComparisonAbout VNO Vornado Realty Trust
Vornado Realty Trust is a fully integrated real estate investment trust with a portfolio of New York City office, retail, and multifamily assets, and the developer of the new Penn District. While concentrated in New York, the trust also owns assets in both Chicago and San Francisco. It generates revenue in the form of property rentals, fees charged for trade shows, parking revenues, management and leasing fees, etc. Vornado operates in the following reportable segments: New York (its key revenue-generating market) and Other.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.